{"id":"https://openalex.org/W7223099838","doi":"https://doi.org/10.3389/fimmu.2026.1927990","title":"Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial","display_name":"Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial","publication_year":2026,"publication_date":"2026-10-21","ids":{"openalex":"https://openalex.org/W7223099838","doi":"https://doi.org/10.3389/fimmu.2026.1927990","pmid":"https://pubmed.ncbi.nlm.nih.gov/42984708","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13731347"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2026.1927990","doi":"https://doi.org/10.3389/fimmu.2026.1927990","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1927990","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1927990/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1927990/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011420021","display_name":"Haiqi Lu","orcid":"https://orcid.org/0000-0001-9349-3382","observed_orcids":["https://orcid.org/0000-0001-9349-3382"]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Haiqi Lu","raw_affiliation_strings":["Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121484046","display_name":"Xufei Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xufei Wang","raw_affiliation_strings":["Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]},{"raw_affiliation_string":"Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159179227","display_name":"Zhuo Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhuo Wang","raw_affiliation_strings":["Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003959978","display_name":"Miaoqin Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Miaoqin Chen","raw_affiliation_strings":["Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100568184","display_name":"Yiming Zhong","orcid":"https://orcid.org/0009-0009-8613-6665","observed_orcids":["https://orcid.org/0009-0009-8613-6665"]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yiming Zhong","raw_affiliation_strings":["Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052565839","display_name":"Lingfeng Ma","orcid":"https://orcid.org/0000-0002-5441-4714","observed_orcids":["https://orcid.org/0000-0002-5441-4714"]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Lingfeng Ma","raw_affiliation_strings":["Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157288697","display_name":"Wanfen Tang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162045","display_name":"Jinhua Central Hospital","ror":"https://ror.org/04z13ha89","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210162045"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wanfen Tang","raw_affiliation_strings":["Department of Medical Oncology, Jinhua Central Hospital/Affiliated Jinhua Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Jinhua Central Hospital/Affiliated Jinhua Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I4210162045","https://openalex.org/I76130692"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159202847","display_name":"Xian Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802390878","display_name":"Sir Run Run Shaw Hospital","ror":"https://ror.org/00ka6rp58","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I2802390878"]},{"id":"https://openalex.org/I76130692","display_name":"Zhejiang University","ror":"https://ror.org/00a2xv884","country_code":"CN","type":"education","lineage":["https://openalex.org/I76130692"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xian Wang","raw_affiliation_strings":["Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]},{"raw_affiliation_string":"Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","institution_ids":["https://openalex.org/I2802390878","https://openalex.org/I76130692"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5159194515","display_name":"Guangliang Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I19820366","display_name":"Chinese Academy of Sciences","ror":"https://ror.org/034t30j35","country_code":"CN","type":"government","lineage":["https://openalex.org/I19820366"]},{"id":"https://openalex.org/I4210098734","display_name":"Zhejiang Cancer Hospital","ror":"https://ror.org/0144s0951","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210098734"]},{"id":"https://openalex.org/I4405261136","display_name":"Hangzhou Institute of Medicine, Chinese Academy of Sciences","ror":"https://ror.org/04vs9wp72","country_code":"CN","type":"government","lineage":["https://openalex.org/I19820366","https://openalex.org/I4405258660","https://openalex.org/I4405261136"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Guangliang Li","raw_affiliation_strings":["Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences","institution_ids":["https://openalex.org/I19820366","https://openalex.org/I4210098734","https://openalex.org/I4405261136"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5011420021","https://openalex.org/A5159194515","https://openalex.org/A5159202847"],"corresponding_institution_ids":["https://openalex.org/I19820366","https://openalex.org/I2802390878","https://openalex.org/I4210098734","https://openalex.org/I4405261136","https://openalex.org/I76130692"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.73273175,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1927990","last_page":"1927990"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.7372999787330627,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.7372999787330627,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.24459999799728394,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.010599999688565731,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eribulin-mesylate","display_name":"eribulin mesylate","score":0.9660000205039978},{"id":"https://openalex.org/keywords/ivonescimab","display_name":"ivonescimab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.968999981880188},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8859999775886536},{"id":"https://openalex.org/keywords/locally-advanced-breast-cancer","display_name":"locally advanced breast cancer","score":0.9670000076293945},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8259999752044678},{"id":"https://openalex.org/keywords/microtubule-inhibitors","display_name":"microtubule inhibitors","score":0.8209999799728394},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7379999756813049},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.800000011920929},{"id":"https://openalex.org/keywords/immunotherapy-resistance","display_name":"immunotherapy resistance","score":0.828000009059906},{"id":"https://openalex.org/keywords/angiogenesis","display_name":"angiogenesis","score":0.6480000019073486},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8029999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9143000245094299},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6912999749183655},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6326000094413757},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6107000112533569},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5985000133514404},{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.5879999995231628},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5425000190734863},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5042999982833862},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.4787999987602234},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4661000072956085},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4426000118255615},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.37880000472068787},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.3675000071525574},{"id":"https://openalex.org/C2780839634","wikidata":"https://www.wikidata.org/wiki/Q5922406","display_name":"Inflammatory breast cancer","level":4,"score":0.3562000095844269},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3163999915122986},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3149999976158142},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.30410000681877136},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.3001999855041504},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.29600000381469727},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.29260000586509705},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.29179999232292175},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.2727000117301941},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.2705000042915344},{"id":"https://openalex.org/C502991105","wikidata":"https://www.wikidata.org/wiki/Q5133849","display_name":"Clinical research","level":2,"score":0.2702000141143799},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2669000029563904},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.26570001244544983},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2637999951839447},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2632000148296356},{"id":"https://openalex.org/C2777877232","wikidata":"https://www.wikidata.org/wiki/Q17144704","display_name":"Immunogenic cell death","level":4,"score":0.25600001215934753},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.25209999084472656}],"mesh":[{"descriptor_ui":"D000095662","descriptor_name":"Polyether Polyketides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005663","descriptor_name":"Furans","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005663","descriptor_name":"Furans","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005663","descriptor_name":"Furans","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007659","descriptor_name":"Ketones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007659","descriptor_name":"Ketones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007659","descriptor_name":"Ketones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2026.1927990","doi":"https://doi.org/10.3389/fimmu.2026.1927990","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1927990","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1927990/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmid:42984708","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42984708","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13731347","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13731347/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:ebd9fc78ab70456ea867ba5f662eeffb","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/ebd9fc78ab70456ea867ba5f662eeffb","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2026.1927990","doi":"https://doi.org/10.3389/fimmu.2026.1927990","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2026.1927990","pdf_url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1927990/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Study Protocol","id":"https://openalex.org/study-designs/study-protocol"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223099838.pdf","grobid_xml":"https://content.openalex.org/works/W7223099838.grobid-xml"},"referenced_works_count":59,"referenced_works":["https://openalex.org/W2018563247","https://openalex.org/W2019607817","https://openalex.org/W2022075549","https://openalex.org/W2053242178","https://openalex.org/W2103563357","https://openalex.org/W2126275851","https://openalex.org/W2127152525","https://openalex.org/W2137545466","https://openalex.org/W2166573361","https://openalex.org/W2387959609","https://openalex.org/W2605456582","https://openalex.org/W2753016107","https://openalex.org/W2785041354","https://openalex.org/W2791328450","https://openalex.org/W2805354595","https://openalex.org/W2888460025","https://openalex.org/W2990398119","https://openalex.org/W3011819195","https://openalex.org/W3013347515","https://openalex.org/W3025022288","https://openalex.org/W3084409519","https://openalex.org/W3109853980","https://openalex.org/W3131675717","https://openalex.org/W3150836655","https://openalex.org/W3184964864","https://openalex.org/W3213834237","https://openalex.org/W4200098699","https://openalex.org/W4207033714","https://openalex.org/W4281698779","https://openalex.org/W4289397468","https://openalex.org/W4291786797","https://openalex.org/W4292838584","https://openalex.org/W4295082389","https://openalex.org/W4306829859","https://openalex.org/W4372214946","https://openalex.org/W4378627997","https://openalex.org/W4378781718","https://openalex.org/W4383301800","https://openalex.org/W4385556935","https://openalex.org/W4386223335","https://openalex.org/W4387700258","https://openalex.org/W4388744602","https://openalex.org/W4390670334","https://openalex.org/W4391256169","https://openalex.org/W4393410416","https://openalex.org/W4394689596","https://openalex.org/W4394980210","https://openalex.org/W4396973236","https://openalex.org/W4399201775","https://openalex.org/W4402494964","https://openalex.org/W4406431707","https://openalex.org/W4408724169","https://openalex.org/W4409644734","https://openalex.org/W4411673676","https://openalex.org/W7161014110","https://openalex.org/W7165007685","https://openalex.org/W7168236183","https://openalex.org/W7202250977","https://openalex.org/W7204252937"],"related_works":["https://openalex.org/W4411286442","https://openalex.org/W7202250977","https://openalex.org/W4402561371","https://openalex.org/W2399610840","https://openalex.org/W3138947068","https://openalex.org/W4247108248","https://openalex.org/W7129331557","https://openalex.org/W2593352313","https://openalex.org/W3029858610","https://openalex.org/W2791885889"],"abstract_inverted_index":{"Background:":[0],"Advanced":[1],"triple-negative":[2],"breast":[3],"cancer":[4],"(TNBC)":[5],"has":[6],"an":[7],"extremely":[8],"poor":[9],"prognosis,":[10],"and":[11,69,104,171,183,185,203,220],"current":[12],"therapies":[13],"offer":[14],"limited":[15],"benefits":[16],"for":[17,109,213],"patients":[18,89],"with":[19,59,90],"low":[20],"programmed":[21],"cell":[22],"death":[23],"ligand":[24],"1(PD-L1)":[25],"expression.":[26],"This":[27,77,190],"study":[28],"innovatively":[29],"proposes":[30],"a":[31,45,79],"\"novel":[32],"chemotherapy":[33],"+":[34],"bispecific":[35,62,205],"antibody\"":[36],"model.":[37],"Eribulin":[38],"Mesylate":[39],"(hereinafter":[40],"referred":[41],"to":[42,71,86,147,195],"as":[43],"Eribulin),":[44],"novel":[46,209],"microtubule":[47],"inhibitor,":[48],"kills":[49],"tumor":[50,55],"cells":[51],"while":[52],"remodeling":[53],"the":[54,60,129,178,197,214],"microenvironment.":[56],"When":[57],"combined":[58],"PD-1/VEGF":[61],"antibody":[63,206],"Ivonescimab,":[64],"it":[65],"concurrently":[66],"dismantles":[67],"immunosuppression":[68],"angiogenesis":[70],"synergistically":[72],"overcome":[73],"immunotherapy":[74],"resistance.":[75],"Methods:":[76],"is":[78,128,193],"multicenter,":[80],"open-label,":[81],"single-arm":[82],"clinical":[83,226],"trial":[84],"designed":[85],"enroll":[87],"29":[88],"locally":[91],"advanced":[92],"or":[93,113,116],"metastatic":[94,218],"TNBC":[95,219],"who":[96,105],"have":[97,117],"not":[98],"received":[99],"prior":[100],"systemic":[101],"anticancer":[102],"therapy,":[103,115],"are":[106],"either":[107],"ineligible":[108],"radical":[110],"surgical":[111],"resection":[112],"local":[114],"experienced":[118],"disease":[119],"progression":[120],"following":[121],"postoperative":[122],"adjuvant":[123],"therapy.":[124],"The":[125],"primary":[126],"endpoint":[127],"objective":[130],"response":[131,169],"rate":[132],"(ORR)":[133],"assessed":[134],"by":[135],"Investigator":[136],"Assessment":[137],"(INV)":[138],"at":[139],"each":[140],"participating":[141],"center":[142],"based":[143],"on":[144],"strict":[145],"adherence":[146],"Response":[148],"Evaluation":[149],"Criteria":[150],"in":[151],"Solid":[152],"Tumors":[153],"version":[154],"1.1(RECIST":[155],"v1.1)":[156],"criteria.":[157],"Secondary":[158],"endpoints":[159,174],"include":[160],"progression-free":[161],"survival":[162,165],"(PFS),":[163],"overall":[164],"(OS),":[166],"duration":[167],"of":[168,200,217],"(DoR),":[170],"safety.":[172],"Exploratory":[173],"involve":[175],"potential":[176],"biomarkers,":[177],"correlation":[179],"between":[180],"PD-L1":[181],"expression":[182],"efficacy,":[184],"patient-reported":[186],"outcomes":[187],"(PROs).":[188],"Discussion:":[189],"combination":[191],"regimen":[192],"expected":[194],"leverage":[196],"synergistic":[198],"advantages":[199],"\"chemotherapy-promoted":[201],"immunity":[202],"potent":[204],"efficacy,\"":[207],"providing":[208],"evidence-based":[210],"medical":[211],"evidence":[212],"first-line":[215],"treatment":[216],"thereby":[221],"effectively":[222],"addressing":[223],"significant":[224],"unmet":[225],"needs.":[227],"Clinical":[228],"Trial":[229],"Registration:":[230],"http://www.chictr.org.cn/,":[231],"identifier":[232],"ChiCTR2600117652.":[233]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-22T00:00:00"}